文献速递炎症性肠病

综述:炎症性肠病中的肠道微生物组——微生物管理的途径

Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.
PubMed 文献 · Aliment Pharmacol Ther · 2017-10-16

该综述通过Medline检索肠道微生物组与炎症性肠病相关文献,评估流行病学、实验和临床证据。疾病缓解与复发均伴随黏膜和管腔样本的微生物变化,克罗恩病中物种丰富度丢失被广泛观察。现有治疗策略分为增加、减少或间接调节微生物组三类,粪菌移植似最有前景,但研究设计和方法学差异使结果难以转化为临床实践。

要点

  • 疾病缓解与复发均与黏膜和管腔样本的微生物变化相关。
  • 克罗恩病中物种丰富度丢失已被广泛观察到。
  • 现有微生物组调节策略相对不精细,粪菌移植似最有前景但研究设计差异限制临床转化。

核心结论

  • 现有调节肠道微生物组的方法相对不精细。
  • 未来微生物组调节治疗前景光明,多种新策略和新技术即将出现。
  • 在炎症性肠病中忽视微生物组不是选项。

研究设计与样本

  • 综述类文章,通过Medline检索肠道微生物组、炎症性肠病、溃疡性结肠炎、克罗恩病、粪菌移植和饮食干预等相关文献。

主要发现

  • 疾病缓解和复发与黏膜和管腔样本中的微生物变化相关。
  • 克罗恩病中物种丰富度丢失已被广泛观察到。
  • 现有治疗方法大致分为三类:增加、减少或间接调节微生物组。
  • 粪菌移植似最有前景,但研究设计和方法学差异使结果目前难以转化为临床实践。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The concept of an altered collective gut microbiota rather than identification of a single culprit is possibly the most significant development in inflammatory bowel disease research. We have entered the "omics" era, which now allows us to undertake large-scale/high-throughput microbiota analysis which may well define how we approach diagnosis and treatment of inflammatory bowel disease (IBD) in the future, with a strong steer towards personalised therapeutics. AIM: To assess current epidemiological, experimental and clinical evidence of the current status of knowledge relating to the gut microbiome, and its role in IBD, with emphasis on reviewing the evidence relating to microbial therapeutics and future microbiome modulating therapeutics. METHODS: A Medline search including items 'intestinal microbiota/microbiome', 'inflammatory bowel disease', 'ulcerative colitis', 'Crohn's disease', 'faecal microbial transplantation', 'dietary manipulation' was performed. RESULTS: Disease remission and relapse are associated with microbial changes in both mucosal and luminal samples. In particular, a loss of species richness in Crohn's disease has been widely observed. Existing therapeutic approaches broadly fall into 3 categories, namely: accession, reduction or indirect modulation of the microbiome. In terms of microbial therapeutics, faecal microbial transplantation appears to hold the most promise; however, differences in study design/methodology mean it is currently challenging to elegantly translate results into clinical practice. CONCLUSIONS: Existing approaches to modulate the gut microbiome are relatively unrefined. Looking forward, the future of microbiome-modulating therapeutics looks bright with several novel strategies/technologies on the horizon. Taken collectively, it is clear that ignoring the microbiome in IBD is not an option.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. McIlroy J, Ianiro G, Mukhopadhya I, et al. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther. 2017. PMID: 29034981. doi:10.1111/apt.14384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。